好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Movement Disorders
P8 - Poster Session 8 (11:45 AM-12:45 PM)
5-002

To assess the frequency and outcomes of impulsivity in study participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for the treatment of Parkinson’s Disease (PD).

The relationship between STN-DBS and impulse control disorders (ICD) has been complex and resulted in largely retrospective uncontrolled studies. These studies have yielded heterogeneous outcomes. Small retrospective studies evaluating participants before and after STN-DBS surgery have however revealed both positive and negative results. Many have shown potential for reduction of pre-existing behaviors and others have revealed worsening. De novo ICDs following STN-DBS have also been reported. There is limited knowledge regarding the factors and interactions accounting for these different outcomes.

INTREPID (ClinicalTrials.gov: NCT01839396) is a multi-center, prospective, double-blinded, randomized controlled trial. Participants with advanced PD were implanted bilaterally in the STN and completed a neuropsychological battery at screening (prior to DBS) and at follow-up (12-months). Impulsivity was examined using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale (QUIP-RS). A higher QUIP-RS score indicated greater severity (frequency) of symptoms. Total QUIP-RS scores (ranged from 0-64) and ratings for individual ICD behavior(s) were also evaluated. Clinically significant ICD was defined as a QUIP-RS score >22.

At 1-year post STN-DBS, 32 of 160 participants (20%) reported >5 point improvement in QUIP-RS ICD scores, and 7 (4.3%) showed a >10-point improvement. Nineteen (11.8%) participants had a >5 point worsening, and 8 (5%) reported a worsening of > 10. Analysis of relevant demographic information, appearance of ICD and clinical factors including antiparkinsonian medications, lead location, programming settings and structural as well as functional connectivity will be presented.

The data  at 1-year follow-up following bilateral STN-DBS revealed both improvement and worsening in ICDs as well as some de novo cases. Clinicians should be aware of these critically important management issues and appropriate pre-operative counseling and post-operative monitoring should be employed.

Authors/Disclosures
Tamara Stiep, MD (UCSF Movement Disorders Clinic)
PRESENTER
Dr. Stiep has nothing to disclose.
Alexander I. Troster, PhD (Barrow Neurological Institute) Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Therapeutics. Dr. Troster has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cambridge University Press/International Neuropsychological Society. The institution of Dr. Troster has received research support from Barrow Neurological Foundation. Dr. Troster has received publishing royalties from a publication relating to health care.
Adolfo Ramirez Zamora, MD (University of Louisville) Dr. Ramirez Zamora has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel therapeutics. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving as a Consultant for NeuroPacs. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota Inc. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maplight. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. The institution of Dr. Ramirez Zamora has received research support from Parkinsons Foundation.
Roshini Jain Roshini Jain has received personal compensation for serving as an employee of Boston Scientific. Roshini Jain has received stock or an ownership interest from Boston Scientific.
Lilly Chen (Boston Scientific) Lilly Chen has received personal compensation for serving as an employee of Boston Scientific .
Michael S. Okun, MD, FAAN (University of Florida) Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.